(131I)Meta-iodobenzylguanidine scintigraphy and selective venous catheterization after thyroidectomy for medullary thyroid carcinoma

  • Giovanni Lupoli
  • Gaetano Lombardi
  • Nicola Panza
  • Bernadette Biondi
  • Giovanni Pacilio
  • Secondo Lastoria
  • Marco Salvatore


Fifteen patients with medullary carcinoma of the thyroid (MCT), who had persistently elevated levels of serum calcitonin (CT) and carcinoembryonic antigen (CEA) after total thyroidectomy, were studied in order to localize the sites of the recurrent disease. Routine diagnostic examinations, including ultrasonography (US) and computed axial tomography (CAT), were carried out in all the cases. Scintigraphy with radio-iodinated meta-iodobenzylguanidine ((131I)-MIBG) was performed in 13 cases; selective venous catheterization (SVC) to reveal a gradient of CT levels was performed in 12 cases. Ten patients underwent both (l31I)-MIBG scintigraphy and SVC. US and CAT revealed the sites of recurrent tumor in only 4 out of the total 15 patients. SVC in basal conditions showed the presence of small metastases in 2 cases, and after intravenous stimulus with pentagastrin in 4 others. The MIBG scan showed metastatic foci of sporadic MCT in 2 patients, residual medullary thyroid tissue in 4 others, and a pheochromocytoma in a previously undiagnosed patient with Sipple’s syndrome. More particularly, MIBG scan and SVC showed the localization of residual or metastatic tumor in 10 cases. In all 10 cases, results of the MIBG scan and SVC were confirmed as true positive by subsequent surgery and histopathologic examination. The conclusions of this study were twofold: (1) in the follow-up of MCT patients with persistently elevated CT and CEA levels, positive US and CAT findings make the MIBG scan useful, if positive, only to determine the nature of the lesion; (2) the association of the two approaches (MIBG scan and SVC) in patients with increased levels of CT and CEA but negative results of routine diagnostic examination can be useful to detect occult rnicrometastases, thus permitting an accurate clinicopathologic staging of the disease.

Key words

Meta-iodobenzylguanidine Selective venous catheterization Medullary thyroid carcinoma 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Tashjian A H Jr, Howland B G, Melvin K E W, Hill C S Jr: Immunoassay of human calcitonin, clinical measurement, relation to serum calcium and studies in patients with medullary carcinoma.N Engl J Med 283, 890 (1970).CrossRefGoogle Scholar
  2. 2.
    Deftos L J: Radioimmunoassay for calcitonin in medullary thyroid carcinoma.JAMA 227, 403 (1974).PubMedCrossRefGoogle Scholar
  3. 3.
    Stepanas A V, Samaan N A, Stratton C HJr, Hickey R C: Medullary thyroid carcinoma. Importance of serial serum calcitonin measurement.Cancer 43, 825 (1979).PubMedCrossRefGoogle Scholar
  4. 4.
    Busnardo B, Girelli M E, Simioni N, Nacamulli D, Busetto E: Non parallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma.Cancer 53, 278 (1984).PubMedCrossRefGoogle Scholar
  5. 5.
    Wieland D M, Wu J L, Brown L Eet al.: Radiolabeled adrenergic neuron blocking agents: adrenomedullary imaging with 131-1 iodobenzylguanicline.J nucl Med 21, 349 (1980).PubMedGoogle Scholar
  6. 6.
    Treuner J, Feine V, Neithhammer Det al.: Scinti-graphic imaging of neurobiastoma with131I-m-iodobenzylguanicline.Lancet 1, 333 (1984).PubMedCrossRefGoogle Scholar
  7. 7.
    Van Moll L, McEvan A J, Shapiro Bet al.: Iocline-131 MIBG scintigraphy of neuroendocrine tumors other than pheochromocytoma and neurobiastoma.J nucl Med 28, 979 (1987).Google Scholar
  8. 8.
    Endo K, Shiomi K, Kasagi Ket al.: Imaging of medullary thyroid carcinoma with131I-MIBG.Lancet 2, 333 (1984).Google Scholar
  9. 9.
    Connell J M C, Hilditch T E, Elliott A, Semple P F:131I-MIBG and medullary carcinoma of the thyroid.Lancet 2, 1273 (1984).PubMedCrossRefGoogle Scholar
  10. 10.
    Wells S A, Bayling S B, Johnsrude I Set al.: Thyroid venous catheterization in the early diagnosis of familial medullary thyroid carcinoma.Ann Surg 196, 505 (1982).PubMedCrossRefGoogle Scholar
  11. 11.
    Lupoli G, Panza N, Biondi Bet al.: Evaluation of plasma calcitonin as marker of medullary thyroid carcinoma by selective venous catheterization.J exp clin Cancer Res 5, 439 (1986).Google Scholar
  12. 12.
    Hellman D E, Kartchner M, Van Antwerp J Det al.: Radioiocline in the treatment of medullary carcinoma of the thyroid.J clin Endocrinol Metab 48, 451 (1979).PubMedGoogle Scholar
  13. 13.
    Panza N, Pacilio G, Campanella Let al.: Cancer antigen 125, tissue polypeptide antigen, carcinoembryonic antigen and beta-chain human chorionic gonadotropin as serum marker of epithelial ovarian carcinoma.Cancer 61, 76 (1988).PubMedCrossRefGoogle Scholar
  14. 14.
    Brennan M F. Cancer of the endocrine system, in De Vita V T Jr, Hellman S, Rosenberg S A (eds):Cancer, Principles & Practice of Oncology, pp. 1179–1191. Philadelphia, J P Lippincott Co (1985).Google Scholar
  15. 15.
    Chong G C, Beahrs O H, Sizemore G W, Woolner L H: Medullary carcinoma of the thyroid gland.Cancer 35, 695 (1975).PubMedCrossRefGoogle Scholar
  16. 16.
    Iwase K, Nagasaka A, Kato Ket al.: Enolase subunits in patients with neuroendocrine tumors.J clin Endo-crinol Me tab 63, 94 (1986).Google Scholar
  17. 17.
    Endo K, Koizumi M, Sakahara Jet al.: Uptake of131I-MIBG by medullary thyroid cancer (Abstr).Eur J nucl Med 11, A17 (1985).CrossRefGoogle Scholar
  18. 18.
    Hilditch T E, Connell J M, Elliott A T, Murray T, Reed N S: Poor results with technetium-99m(V)DMS and iocline 131 MIBG in the imaging of medullary thyroid carcinoma.J nucl Med 26, 1150 (1986).Google Scholar
  19. 19.
    Poston G J, Thomas A M K, MacDonald D Wet al.: Imaging of metastatic medullary carcinoma of the thyroid with131I-Meta-iodobenzylguanicline.Nucl Med Commun 7, 215 (1986).PubMedCrossRefGoogle Scholar
  20. 20.
    Sone T, Fukunaga M, Otsuka Net al.: Metastatic medullary thyroid cancer: localization with iocline-131 meta-iodobenzyl-guanicline.J nucl Med 26, 604 (1985).PubMedGoogle Scholar
  21. 21.
    Baulieu J L, Guilloteau D, Delisle M Jet al.: Radioioclinated meta-iodobenzylguanicline uptake in medullary thyroid cancer.Cancer 60, 2189 (1987).PubMedCrossRefGoogle Scholar
  22. 22.
    Itoh H, Sugie K, Toyooka Set al.: Detection of metastatic medullary thyroid cancer with131I-MIBG scans in Sipple’s syndrome. Case report.Eur J nucl Med 11, 502 (1986).PubMedCrossRefGoogle Scholar
  23. 23.
    Graze K, Spiler I J, Tashjian A HJret al.: Natural history of familial medullary thyroid carcinoma. Effect of a program for early diagnosis.N Engl J Med 299, 980 (1978).PubMedGoogle Scholar
  24. 24.
    Hoefnegel C A, Voute P A, De Kraker J, Marcuse H R: Radionuclide diagnosis and therapy of neural crest tumors using radioiocline I-131-MIBG.J nucl Med 28, 308 (1987).Google Scholar
  25. 25.
    Troncone L, Rufini V, Montemaggi P, Bambece S: Can I-131 therapy be usefully integrated in the treatment of medullary thyroid carcinoma (MTC)? Preliminary results.Nuklearmedizin/Nudearmedicine 26, 633 (1988).Google Scholar
  26. 26.
    Clarke S E M, Lazarus C R, Fogelman I, Malsey M N. Technetium-99(V)-DMSA in the imaging of medullary thyroid carcinoma.J Nucl Med 28, 252 (1987).Google Scholar
  27. 27.
    Clarke S E M, Lazarus C R, Mistry R, Malsey M N. The role of Technetium 99-m pentavalent DMSA in the management of patients with medullary carcinoma of the thyroid.Br J Rad 60, 1089 (1987).CrossRefGoogle Scholar
  28. 28.
    Clarke S E M, Lazarus C R, Wright P, Sampson C, Malsey M N: Pentavalent (99mTc)DMSA, (131I)MIBG and (99mTc)MDP. An evaluation of three imaging techniques in patients with medullary carcinoma of the thyroid.J nucl Med 29, 33 (1988).PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 1991

Authors and Affiliations

  • Giovanni Lupoli
    • 1
  • Gaetano Lombardi
    • 1
  • Nicola Panza
    • 1
  • Bernadette Biondi
    • 1
  • Giovanni Pacilio
    • 2
  • Secondo Lastoria
    • 3
  • Marco Salvatore
    • 3
  1. 1.Cattedra di EndocrinologiaDipartimento di Patologia Sistematica, Seconda Facoltà di Medicina e ChirurgiaNaplesItaly
  2. 2.Divisione di OncologiaOspedale CardarelliNaplesItaly
  3. 3.Cattedra di Medicina NucleareIstituto di Scienze Radiologiche, Seconda Facoltà di Medicina e ChirurgiaNaplesItaly

Personalised recommendations